News

• Basilea reports preclinical data on anti-cancer activity of novel oncology drug candidate BAL0891 at ESMO TAT congress
  03/08/2022 / 07:15 - GlobeNewswire
•  
• Basilea to become a leading anti-infectives company backed by strong financial results 2021
  02/15/2022 / 07:15 - GlobeNewswire
•  
• Basilea reports updated interim results for iCCA patients with FGFR2 mutations and amplifications from phase 2 study FIDES-01 at ASCO GI Cancers Symposium
  01/24/2022 / 07:15 - GlobeNewswire
•  
• Basilea announces approval of antifungal Cresemba® (isavuconazole) for invasive aspergillosis in China
  01/13/2022 / 07:15 - GlobeNewswire
•  
• Basilea announces completion of patient enrolment in phase 3 ERADICATE study investigating ceftobiprole in bloodstream infections
  01/11/2022 / 07:15 - GlobeNewswire
•  
• Basilea exceeds 2021 financial guidance on preliminary revenue and year-end cash-position
  01/10/2022 / 07:15 - GlobeNewswire
•  
• Strong Cresemba® (isavuconazole) sales by Astellas in the U.S. trigger CHF 15 million sales milestone payment to Basilea
  01/07/2022 / 07:15 - GlobeNewswire
•  
• Basilea reports on portfolio progress made in 2021
  01/06/2022 / 07:15 - GlobeNewswire
•  
• Basilea receives USD 10 million milestone payment related to approval of antifungal Cresemba® (isavuconazole) in China
  12/21/2021 / 07:15 - GlobeNewswire
•  
• Basilea announces FDA approval of Investigational New Drug application for novel oncology drug candidate BAL0891
  12/17/2021 / 07:15 - GlobeNewswire
•  
• Continued strong Cresemba® (isavuconazole) sales by Pfizer trigger USD 10 million sales milestone payment to Basilea
  12/08/2021 / 07:15 - GlobeNewswire
•  
• Basilea announces submission of Investigational New Drug application for novel oncology drug candidate BAL0891
  11/16/2021 / 07:15 - GlobeNewswire
•  
• Basilea presents preclinical data on synergy between derazantinib and paclitaxel in gastric tumor models at ANE Conference
  10/11/2021 / 07:15 - GlobeNewswire
•  
• Basilea’s partner Asahi Kasei Pharma filed New Drug Application for the marketing authorization of isavuconazole in Japan
  09/30/2021 / 07:15 - GlobeNewswire
•  
• Basilea presents full safety and efficacy data set on derazantinib in patients with FGFR2 fusion-positive iCCA at ESMO congress
  09/17/2021 / 07:15 - GlobeNewswire